share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募资说明书
美股sec公告 ·  05/16 12:45
Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its previous prospectus dated April 2, 2024, with details from its quarterly report filed with the SEC. The supplement pertains to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.4408 per share as of May 14, 2024. The supplement, which includes the attached Quarterly Report, provides updated information and should be read in conjunction with the original prospectus. Panbela Therapeutics has incurred significant losses since inception and continues to face a high degree of risk, as detailed in the 'Risk Factors' section of the Prospectus and Quarterly Report. The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving success in its development efforts and commercialization of its product candidates.
Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its previous prospectus dated April 2, 2024, with details from its quarterly report filed with the SEC. The supplement pertains to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.4408 per share as of May 14, 2024. The supplement, which includes the attached Quarterly Report, provides updated information and should be read in conjunction with the original prospectus. Panbela Therapeutics has incurred significant losses since inception and continues to face a high degree of risk, as detailed in the 'Risk Factors' section of the Prospectus and Quarterly Report. The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving success in its development efforts and commercialization of its product candidates.
Panbela Therapeutics, Inc.于2024年5月15日提交了招股说明书补充文件，以更新和补充其先前于2024年4月2日发布的招股说明书中的信息，详细信息来自其向美国证券交易委员会提交的季度报告。该补充文件涉及发行8,750,000股普通股，标的先前发行的E类和F类普通股购买权证。这些股票最初是在注册声明上注册的，并在OTCQB上市，股票代码为 “PBLA”。截至2024年5月14日，上次公布的普通股销售价格为每股0.4408美元。该补编包括所附的季度报告，提供了最新的信息，应与原始招股说明书一起阅读。正如招股说明书和季度报告的 “风险因素” 部分所详述的那样，Panbela Therapeutics自成立以来就蒙受了重大损失，并且继续面临高度的风险。该公司能否继续经营取决于能否获得额外的融资，以及在开发工作和候选产品的商业化方面取得成功。
Panbela Therapeutics, Inc.于2024年5月15日提交了招股说明书补充文件，以更新和补充其先前于2024年4月2日发布的招股说明书中的信息，详细信息来自其向美国证券交易委员会提交的季度报告。该补充文件涉及发行8,750,000股普通股，标的先前发行的E类和F类普通股购买权证。这些股票最初是在注册声明上注册的，并在OTCQB上市，股票代码为 “PBLA”。截至2024年5月14日，上次公布的普通股销售价格为每股0.4408美元。该补编包括所附的季度报告，提供了最新的信息，应与原始招股说明书一起阅读。正如招股说明书和季度报告的 “风险因素” 部分所详述的那样，Panbela Therapeutics自成立以来就蒙受了重大损失，并且继续面临高度的风险。该公司能否继续经营取决于能否获得额外的融资，以及在开发工作和候选产品的商业化方面取得成功。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息